Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Ford

Showing results (1381-1390 of 1,411) with videos related to

Pageof 142
Sort By:
Health Technology Assessment (Winchester, England)|October 14, 2024
Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCTAlexandra Wright-Hughes, Alexander C Ford, Sarah L Alderson, et al.
Breast Cancer Research and Treatment|June 8, 2011
Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathwaysCatherine Ibarra-Drendall, Michelle M Troch, William T Barry, et al.
Lancet (London, England)|October 20, 2023
Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trialAlexander C Ford, Alexandra Wright-Hughes, Sarah L Alderson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 27, 2025
Glycoprotein L-deleted single-cycle rhesus cytomegalovirus vectors elicit MHC-E-restricted CD8+ T cells that protect against SIVScott G Hansen, John B Schell, Emily E Marshall, et al.
JCI Insight|February 7, 2023
Late gene expression-deficient cytomegalovirus vectors elicit conventional T cells that do not protect against SIVScott G Hansen, Jennie L Womack, Wilma Perez, et al.
United European Gastroenterology Journal|June 13, 2022
Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and MotilityEdoardo Savarino, Fabiana Zingone, Brigida Barberio, et al.
Cancer|December 26, 2022
Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disordersZeinab A M Afify, Mary M Taj, Manuela Orjuela-Grimm, et al.
Science (New York, N.Y.)|March 26, 2021
Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacyMarieke C Verweij, Scott G Hansen, Ravi Iyer, et al.
Nature Medicine|August 8, 2018
Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral reboundAfam A Okoye, Scott G Hansen, Mukta Vaidya, et al.
Nature|September 13, 2013
Immune clearance of highly pathogenic SIV infectionScott G Hansen, Michael Piatak, Abigail B Ventura, et al.
Pageof 142

Showing results (1381-1390 of 1,411) with videos related to

Sort By:
Pageof 142
Health Technology Assessment (Winchester, England)|October 14, 2024
Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCTAlexandra Wright-Hughes, Alexander C Ford, Sarah L Alderson, et al.
Breast Cancer Research and Treatment|June 8, 2011
Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathwaysCatherine Ibarra-Drendall, Michelle M Troch, William T Barry, et al.
Lancet (London, England)|October 20, 2023
Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trialAlexander C Ford, Alexandra Wright-Hughes, Sarah L Alderson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 27, 2025
Glycoprotein L-deleted single-cycle rhesus cytomegalovirus vectors elicit MHC-E-restricted CD8+ T cells that protect against SIVScott G Hansen, John B Schell, Emily E Marshall, et al.
JCI Insight|February 7, 2023
Late gene expression-deficient cytomegalovirus vectors elicit conventional T cells that do not protect against SIVScott G Hansen, Jennie L Womack, Wilma Perez, et al.
United European Gastroenterology Journal|June 13, 2022
Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and MotilityEdoardo Savarino, Fabiana Zingone, Brigida Barberio, et al.
Cancer|December 26, 2022
Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disordersZeinab A M Afify, Mary M Taj, Manuela Orjuela-Grimm, et al.
Science (New York, N.Y.)|March 26, 2021
Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacyMarieke C Verweij, Scott G Hansen, Ravi Iyer, et al.
Nature Medicine|August 8, 2018
Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral reboundAfam A Okoye, Scott G Hansen, Mukta Vaidya, et al.
Nature|September 13, 2013
Immune clearance of highly pathogenic SIV infectionScott G Hansen, Michael Piatak, Abigail B Ventura, et al.
Pageof 142